Woodcock rules out compounding to lower prices

Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, said Thursday she has ruled out the use of compounding to combat spikes in generic drug prices.

Woodcock told the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee that "there are very great risks" from FDA allowing mass production of compounded drugs to reduce the cost of a generic drug. ...